Diamond Zuchlinski

发表

Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study

R. Braylan, M. Stetler-Stevenson, A. Zingone, 2013, Leukemia & lymphoma.

Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method

S. Steinberg, R. Braylan, M. Stetler-Stevenson, 2015, Leukemia & lymphoma.

Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.

A. Roccaro, I. Ghobrial, A. Zingone, 2014, Cytokine.

Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

S. Steinberg, P. Choyke, M. Faham, 2015, JAMA oncology.

TreatmentWith Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in PatientsWith Smoldering or Newly DiagnosedMultipleMyeloma

S. Steinberg, P. Choyke, M. Faham, 2015 .

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

R. Braylan, J. Trepel, M. Stetler-Stevenson, 2014, Haematologica.

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

S. Steinberg, M. Stetler-Stevenson, W. Figg, 2017, Leukemia & lymphoma.

Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed Multiple Myeloma (MM) Patients

S. Steinberg, P. Choyke, K. Kurdziel, 2013 .

Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd – R) In High Risk Smoldering Multiple Myeloma Patients

S. Steinberg, P. Choyke, K. Kurdziel, 2013 .

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and Dexamethasone (CRd) in Newly Diagnosed Multiple Myeloma (MM) Patients

S. Steinberg, P. Choyke, M. Raffeld, 2012 .

Early Myelodysplastic Changes Present in Substantial Proportion of Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Patients

R. Braylan, A. Zingone, O. Simakova, 2012 .